Weight Watchers Narrows FY26 Outlook As Clinical Subscription Revenue Grows 48%

WW International (Weight Watchers) reported Q3 2026 revenue of $152.9M, down 11% YoY, but narrowed FY26 revenue guidance to $625M-$630M. Clinical subscription revenue grew 48% to $38M, accounting for 25% of total revenue. The company reported net income of $15.1M, up from a $57.5M loss in Q3 2025. Adjusted EBITDA increased 21% YoY to $51.7M. WW stock is trading at $11.57, down 4.69%.

Original reporting
Published Nov 5, 2026, 4:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 4:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$WW
Bearish
medium confidence
Mentioned
$WW
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$WWBearishMed
01

Why it matters

The narrowed guidance may trigger short‑term selling pressure, but the strong clinical segment growth offers a potential catalyst for a rebound.

02

Market read

First report of WW's Q3 results and FY guidance change; material for traders watching consumer discretionary earnings.

03

What to watch

Cash position of $126M provides runway for marketing spend; upcoming product launches may improve future guidance.

Relevance 7/10Novelty 7/10Timing: after-hours reaction

Background

WW International (Weight Watchers) posted Q3 earnings, highlighted a 48% jump in clinical subscription revenue, and narrowed its FY2026 outlook.

Company-level read

Ticker impact

$WWBearishMedium confidence
Context

WW reported Q3 2026 results and narrowed its FY2026 revenue to $625‑$630M and Adjusted EBITDA to $110‑$115M.

Expected impact

likely pressure as the market prices in the lower revenue outlook

Evidence & confidence

Revenue guidance was reduced despite a profit beat, and the stock is already down 4.7%.

Market effects

Weight Watchers' guidance may signal slower consumer discretionary spending on health‑and‑wellness subscriptions.

U.S. small‑cap consumer discretionary segment could see modest downside pressure.

Limited to WW; no broader macro impact.

Counterpoint

The profit beat and strong clinical subscription growth could support a bounce if the market overreacts to the modest guidance reduction.

Key entities

  • Stephen Bye

    CEO of WW, discussed strategic priorities.

  • Felicia DellaFortuna

    CFO of WW, commented on financial performance.

Related articles

$WWMedAI 8/10

What WW International (WW) Said on Its Q3 Earnings Call

WW International reported Q3 earnings, highlighting a 40% YoY increase in clinical subscribers to 174,000, though down from 197,000 in Q2. Behavioral subscription revenue fell 22% to $113.9M, while clinical revenue rose 48% to $38M. Adjusted gross margin reached 74.6%, and marketing expenses declined. The company narrowed its 2026 revenue guidance to $625M-$630M and adjusted EBITDA to $110M-$115M. Cash increased to $126.4M, and debt was reduced by 70%.

$WWMedAI 8/10

WW International Inc (WW) (Q3 2026) Earnings Call Highlights: Clinical Revenue Surges 48%

WW International reported Q3 2026 revenue of $152.9M, down 11% YoY, with behavioral subscription revenue dropping 22%. Clinical revenue surged 48%, but clinical subscribers declined sequentially. Full-year revenue guidance was narrowed to $625-$630M. Core+ subscribers grew 16% YoY, driven by GLP-1 program adoption and virtual experiences. The company expects flat gross margins at ~74% despite clinical mix growth.

$WWMed

WW International, Inc. Q3 2026 Earnings Call Summary

WW International reported Q3 2026 earnings, highlighting a strategic shift to higher-value tiers (Core+ and Med+) generating 50% of revenue. Clinical revenue grew 48% YoY, driven by Med+ and GLP-1 Success Program. Core+ saw subscriber growth for four consecutive quarters. The company expects sustainable growth in 2027, with clinical revenues projected to reach 25% of total revenue. Debt reduced by 70% since 2025, and net income turned positive.

$WWHigh

Why is WW International stock rallying today?

WW International's stock rose 8.6% after Northland Securities initiated coverage with an Outperform rating and $25.00 price target, citing partnerships and long-term recovery potential. Institutional investors increased positions, and the broader market's tech growth theme supported the rally.